Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

MDPI full text link MDPI Free PMC article
Full text links

Actions

Review
.2022 Jan 26;14(3):610.
doi: 10.3390/cancers14030610.

High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations

Affiliations
Review

High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations

Melania Carlisi et al. Cancers (Basel)..

Abstract

The high output heart failure is a clinical condition in which the systemic congestion is associated to a high output state, and it can be observed in a non-negligible percentage of hematological diseases, particularly in multiple myeloma, a condition in which the risk of adverse cardiovascular events may increase, with a worse prognosis for patients. For this reason, though an accurate literature search, we provided in this review a complete overview of different pathogenetic mechanisms responsible for high output heart failure in multiple myeloma. Indeed, this clinical finding is present in the 8% of multiple myeloma patients, and it may be caused by artero-venous shunts, enhanced angiogenesis, glutamminolysis, hyperammonemia and hemorheological alterations with increase in plasma viscosity. The high output heart failure in multiple myeloma is associated with significant morbidity and mortality, emphasizing the need for a multidisciplinary approach.

Keywords: angiogenesis; artero-venous fistulae; glutamminolysis; high output heart failure; hyperammonemia; multiple myeloma; plasma viscosity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathogenetic mechanisms and common causes of high-output heart failure.
Figure 2
Figure 2
Factors linked to the high-output heart failure (HOHF) in Multiple Myeloma.
See this image and copyright information in PMC

References

    1. Anand I.S., Florea V.G. High output cardiac failure. Curr. Treat. Options Cardiovasc. Med. 2001;3:151–159. doi: 10.1007/s11936-001-0070-1. - DOI - PubMed
    1. Mehta P.A., Dubrey S.W. High output heart failure. QJM. 2009;102:235–241. doi: 10.1093/qjmed/hcn147. - DOI - PubMed
    1. Singh S., Sharma S. Current Treatment Options in Cardiovascular Medicine. StatPearls Publishing; Treasure Island, FL, USA: 2021. High-Output Cardiac Failure.
    1. Reddy Y.N.V., Melenovsky V., Redfield M.M., Nishimura R.A., Borlaug B.A. High-Output Heart Failure: A 15-Year Experience. J. Am. Coll. Cardiol. 2016;68:473–482. doi: 10.1016/j.jacc.2016.05.043. - DOI - PubMed
    1. Plummer C., Driessen C., Szabo Z., Mateos M.-V. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:26. doi: 10.1038/s41408-019-0183-y. - DOI - PMC - PubMed

Publication types

LinkOut - more resources

Full text links
MDPI full text link MDPI Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2026 Movatter.jp